An Exploration of the Experience of Dapagliflozin in Clinical Practice

Overview

Journal Future Sci OA

Specialty Biotechnology

Date 2022 Dec 2

PMID 36457541

Authors

Anuba Paulvarnan Anitha

Swetha Balasubramanian

Arun Gopal Ramalingam

Shini Rubina Samuel Kennady

Nila Ganamurali

Dhivya Dhanasekaran

Sarvesh Sabarathinam

Affiliations

Soon will be listed here.

Abstract

Despite the availability of established treatments, heart failure (HF) is associated with a poor prognosis and suboptimal management, highlighting the need for new treatment and prevention options. It is suggested that sodium-glucose cotransporters 2 inhibitors can provide a beneficial therapeutic approach to significantly lower the disease burden associated with cardiovascular illness in both patients with and without Type 2 diabetes mellitus. This review focuses on the therapeutic aspects of dapagliflozin in clinical practice. Future studies may intend to confirm the significant clinical benefits of sodium-glucose cotransporter-2 inhibitors.

Citing Articles

Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells.

Alsereidi F, Khashim Z, Marzook H, Al-Rawi A, Salomon T, Almansoori M Cardiovasc Diabetol. 2024; 23(1):388.

PMID: 39472869 PMC: 11520772. DOI: 10.1186/s12933-024-02481-y.

Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes.

Addo B, Agyeman W, Ibrahim S, Berchie P Am J Cardiovasc Drugs. 2024; 24(6):753-773.

PMID: 39261443 DOI: 10.1007/s40256-024-00669-x.

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis.

Ali A, Mazroua M, ElSaban M, Najam N, Kothari A, Mansoor T Glob Heart. 2023; 18(1):45.

PMID: 37636033 PMC: 10453961. DOI: 10.5334/gh.1258.

References

Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S . SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. Diabetes Ther. 2018; 9(5):1757-1773. PMC: 6167302. DOI: 10.1007/s13300-018-0471-8. View

Zhai M, Du X, Liu C, Xu H . The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials. Front Clin Diabetes Healthc. 2023; 2:703937. PMC: 10012068. DOI: 10.3389/fcdhc.2021.703937. View

Gilbert R . Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney Int. 2013; 86(4):693-700. DOI: 10.1038/ki.2013.451. View

Yao D, Wang S, Wang M, Lu W . Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway. Mol Med Rep. 2018; 18(4):3625-3630. DOI: 10.3892/mmr.2018.9393. View

Halimi S, Verges B . Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2015; 40(6 Suppl 1):S28-34. DOI: 10.1016/S1262-3636(14)72693-X. View

Verma S, McMurray J . SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61(10):2108-2117. DOI: 10.1007/s00125-018-4670-7. View

Anderson S . Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf. 2014; 5(6):242-54. PMC: 4232499. DOI: 10.1177/2042098614551938. View

Dhillon S . Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019; 79(10):1135-1146. PMC: 6879440. DOI: 10.1007/s40265-019-01148-3. View

Warnes H, Helliwell R, Pearson S, Ajjan R . Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?. Diabetes Ther. 2018; 9(5):1831-1851. PMC: 6167310. DOI: 10.1007/s13300-018-0496-z. View

10.

van der Walt J, Hong Y, Zhang L, Pfister M, Boulton D, Karlsson M . A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e42. PMC: 3674329. DOI: 10.1038/psp.2013.20. View

11.

Nakagawa Y, Kuwahara K . Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients. J Cardiol. 2020; 76(2):123-131. DOI: 10.1016/j.jjcc.2020.03.009. View

12.

Fioretto P, Giaccari A, Sesti G . Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015; 14:142. PMC: 4609166. DOI: 10.1186/s12933-015-0297-x. View

13.

Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta F, Boulton D . Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011; 33(11):1798-808. DOI: 10.1016/j.clinthera.2011.09.011. View

14.

Syed S, Gosavi S, Shami W, Bustamante M, Farah Z, Teleb M . A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015; 13(2):105-12. DOI: 10.2174/1871525714666151106121215. View

15.

Elkind-Hirsch K, Seidemann E, Harris R . A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. Am J Obstet Gynecol MFM. 2020; 2(3):100139. DOI: 10.1016/j.ajogmf.2020.100139. View

16.

Nassif M, Windsor S, Borlaug B, Kitzman D, Shah S, Tang F . The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021; 27(11):1954-1960. PMC: 8604725. DOI: 10.1038/s41591-021-01536-x. View

17.

McMurray J, Solomon S, Inzucchi S, Kober L, Kosiborod M, Martinez F . Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21):1995-2008. DOI: 10.1056/NEJMoa1911303. View

18.

Docherty K, Jhund P, Bengtsson O, DeMets D, Inzucchi S, Kober L . Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care. 2020; 43(11):2878-2881. PMC: 7809714. DOI: 10.2337/dc20-1402. View

19.

Berliner D, Bauersachs J . Drug treatment of heart failure in the elderly. Herz. 2018; 43(3):207-213. PMC: 5934458. DOI: 10.1007/s00059-017-4668-9. View

20.

Gangadharan Komala M, Panchapakesan U, Pollock C, Mather A . Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens. 2012; 22(1):113-9. DOI: 10.1097/MNH.0b013e32835a17ae. View